Pages that link to "Template:ReferenceData"

The following pages link to Template:ReferenceData:

Displaying 50 items.

• Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 5 - 6 (transclusion) (← links)
• Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 7.1 (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.32 (b) (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.32 (c) (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.32 (d) (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.33 (a) - (b) (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.140 (b) (5) (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (1) (transclusion) (← links)
• Reference:USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009 Introduction ; III. B. ; Evaluation (transclusion) (← links)
• Reference:USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024 1.4 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.7.1-002 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix A 3.4 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 4.8-001 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 6-002 (transclusion) (← links)
• Reference:ICH ICH E9 Guideline 1998 Glossary - Dropout (transclusion) (← links)
• Reference:ICH ICH E8 Guideline R1 (2021) 6.2.2 (transclusion) (← links)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.4 - immediate hazard (transclusion) (← links)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.6 (transclusion) (← links)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 Annex A A.6.3-002 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 30-001 (transclusion) (← links)
• Reference:GBR Directive 2001/20/EC 04-Apr-2001 Article 10 (b)-001 (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.30 (b) (ii) (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (a) (4) (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 4.8-002 (transclusion) (← links)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 3.46 (transclusion) (← links)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 7.4.3-002 (transclusion) (← links)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 54 (transclusion) (← links)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 77 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 72 Paragraph 6 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 76 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 77 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 68 Paragraph 1 (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.46 (b) (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 42 (transclusion) (← links)
• Reference:DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 66 (transclusion) (← links)
• Reference:DEU KPBV - Klinische Prüfung-Bewertungsverfahren-Verordnung 31-Jan-2022 § 11 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 30-002 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 31 (transclusion) (← links)
• Reference:GBR Directive 2001/20/EC 04-Apr-2001 Article 10 (b)-002 (transclusion) (← links)
• Reference:GBR Directive 93/42/EEC 11-Oct-2007 Article 15 6. - 7.-001 (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.44 (d) (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.56 (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.7 (c) (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.30 (b) - (c) (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.46 (b) - (c)-001 (transclusion) (← links)
• Reference:USA 21 CFR Part 56 09-Apr-2025 § 56.113-001 (transclusion) (← links)
• Reference:ICH ICH E8 Guideline R1 (2021) 4.3.3.1 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 9.4 (transclusion) (← links)
• Reference:EU EMEA/CHMP/313666/2005 - GUIDELINE ON THE EXPOSURE TO MEDICINAL PRODUCTS DURING PREGNANCY: NEED FOR POST-AUTHORISATION DATA 14-Nov-2005 2.1 (transclusion) (← links)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 ANNEX III Section 2.1 (transclusion) (← links)